MIRM
Mirum Pharmaceuticals, Inc.Healthcare · $5.3B market cap
Verdict
We can't put a fair value on MIRM right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
2 of 5 clear the 10% bar. What are the Big Five?
Follow MIRM
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
1 of the investors we track holds MIRM. In Q1 2026, 1 added. Who we track
Moves in Q1 2026
Added: Polen Capital Management
Insider activity
Since Sep 1, 2026: no open-market purchases, 3 sales worth $3.0M and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Sales
Howe Jolanda
SVP, GLOBAL CONTROLLER · 2026-09-02
Sold
$66K
Peetz Christopher
CHIEF EXECUTIVE OFFICER · 2026-09-01
Sold
$2.1M
Peetz Christopher
CHIEF EXECUTIVE OFFICER · 2026-09-01
Sold
$815K
Other filings
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works